Merck Buys Life Sciences Firm Bio-Techne in $11.3bn Deal
The deal would add Bio-Techne’s multi-omics and precision diagnostics tools and is expected to generate about 140 million euros in annual cost savings.
- On Thursday, June 25, 2026, Merck KGaA, Darmstadt, Germany, announced a definitive agreement to acquire Minneapolis-based Bio-Techne Corporation for $11.3 billion in an all-cash deal priced at $73 per share.
- The acquisition strengthens Merck KGaA's position in high-growth life sciences markets including multi-omics, spatial biology, and cell and gene therapy while adding complementary research and bioprocessing capabilities.
- Merck KGaA expects annual cost synergies of about 140 million euros fully realized by year 3 post-closing. The transaction is expected to close by late 2026 or early 2027, subject to regulatory approval.
- Bio-Techne President and Chief Executive Officer Kim Kelderman called the deal "a testament to the remarkable company our team has built," noting it will provide greater scale to accelerate innovation.
- The deal follows large healthcare transactions this year, including Danaher's $9.9 billion acquisition of Masimo in February, as medical technology and life sciences firms seek to broaden product offerings and gain market share.
31 Articles
31 Articles
Germany’s Merck Pumps Up Life Sciences Biz with $11.3B Bio-Techne Deal
Darmstadt, Germany-based Merck is taking a trip to the Twin Cities to buy Minnesota-based Bio-Techne. The $11.3 billion deal would be Merck’s biggest acquisition in more than 10 years as the drugmaker expands under new CEO Kai Beckmann. Bio-Techne spiked nearly 20% Thursday on the Nasdaq, while Merck KGaA, which hails from Germany as opposed to the US’s Merck & Co., popped about 5%. (While the companies share a name and historical roots, they’v…
Stock Market Today, June 25: Bio-Techne Surges After Merck KGaA Announces $73-Per-Share Cash Acquisition Offer
Bio-Techne (NASDAQ:TECH), a life science reagents, instruments, and bioprocessing tools provider, closed at $70.67, up 20.02%. Merck KGaA’s $73-per-share cash offer drove the move, and investors are watching the deal timetable and any updates on closing conditions. Trading volume reached 51.3M shares, coming in about 1,378% above its three-month average of 3.5M shares.How the markets moved todayThe S&P 500 (SNPINDEX:^GSPC) finished at 7,357, dow…
Coverage Details
Bias Distribution
- 54% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
